Heron Therapeuti (HRTX)
Who owns Heron Therapeuti (HRTX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.6% of the shares are freely tradable; institutional investors hold 83.3%.
Ownership Structure
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Rubric Capital Management LP | 15.87 | 30,046,828 | +0.0 | 03/31/2026 |
| Clearline Capital LP | 6.46 | 12,235,239 | +0.0 | 03/31/2026 |
| BlackRock Inc | 5.34 | 10,106,422 | -1.1 | 03/31/2026 |
| Vanguard Group Inc | 5.19 | 9,820,384 | +16.1 | 12/31/2025 |
| Orbimed Advisors, LLC | 5.19 | 9,816,940 | +0.0 | 03/31/2026 |
| Velan Capital Investment Management LP | 4.62 | 8,753,290 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.13 | 7,810,329 | +0.0 | 03/31/2026 |
| Millennium Management LLC | 4.03 | 7,630,527 | +6.4 | 03/31/2026 |
| Tejara Capital Ltd | 3.35 | 6,336,755 | +23.5 | 03/31/2026 |
| TANG CAPITAL MANAGEMENT LLC | 3.30 | 6,250,000 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 19. Jul 2026 | Collard Craig A | Chief Executive Officer | Other | 13,797 | – | – |
| 19. Jul 2026 | Forbes William P | EVP, Chief Development Officer | Other | 1,101 | 0.47 | 517 |
| 19. Jul 2026 | Forbes William P | EVP, Chief Development Officer | Other | 3,874 | – | – |
| 19. Jul 2026 | Duarte Ira | EVP, Chief Financial Officer | Other | 1,101 | 0.47 | 517 |
| 19. Jul 2026 | Duarte Ira | EVP, Chief Financial Officer | Other | 3,874 | – | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.